Close
Digital Health & Ai Innovation summit 2026
APE 2026

Merge CIMS to provide imaging capabilities for five-year global oncology study

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

FDA May Scrutinize Medical Device Cybersecurity...

The scrutiny by the US Food and Drug Administration...

Recon DL Tool from GE HealthCare...

Pristina Recon DL tool from GE HealthCare which uses...

Abbott to Acquire Cancer Test Maker...

In a recent move, Abbott has gone ahead and...
Merge Healthcare Incorporated, a global corporation dedicated to health IT interoperability solutions, announced that Omnicare Clinical Research, a full service Contract Research Organization (CRO) and subsidiary of Omnicare, Inc, will work with Merge’s clinical trial solutions in a major new clinical trial. A long-standing user of the Merge EDC™ clinical trials application, Omnicare Clinical Research will now will implement Merge CIMS™ as a part of its end-to-end solution for image management of oncology, cardiology and ophthalmology clinical trials.

Mark Penniston, Senior Vice President, Biometrics, Data Management, Clinical Writing and eTechnologies at Omnicare Clinical Research explained, We needed a comprehensive image management solution to support our customer’s imaging requirements for this new clinical trial, as well as for upcoming studies. We feel we can now offer best-of-breed solutions to our Sponsor organizations, particularly those in image-intensive studies such as oncology

Latest stories

Related stories

FDA May Scrutinize Medical Device Cybersecurity More in 2026

The scrutiny by the US Food and Drug Administration...

Recon DL Tool from GE HealthCare Receives a PMA

Pristina Recon DL tool from GE HealthCare which uses...

Abbott to Acquire Cancer Test Maker for Around $21 Billion

In a recent move, Abbott has gone ahead and...

New Policy to Boost Medical Device Industry in China

Beijing has gone on to release a new policy...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »